CAJ | 학술논문

目的：观察自拟乳积方防治乳腺癌患者术后复发转移的临床疗效。方法：回顾性分析109例手术后的乳腺癌患者，根据服药情况分为治疗组(乳积方配合西药组)57例和对照组(西药组)52例，观察患者的总生存率(OS)、无疾病生存率(DFS)、生存质量情况。结果：2组患者在年龄、月经状况、病理类型、临床分期、淋巴结转移情况、激素受体表达情况、Her-2表达情况等基线资料方面，具备方差齐性，差异无统计学意义(P＜0.05)。随访时间13～126月，中位随访时间61月；2组3年DFS率分别为91.4%和68.4%，差异有统计学意义(P＜0.01)；3年OS率分别为100.0%和97.1%，差异无统计学意义(P＞0.05)；5年DFS率分别为63.6%和36.8%，差异有统计学意义(P＜0.01)。5年OS率分别为93.5%和62.5%，差异有统计学意义(P＜0.01)；采用乳腺癌患者生存质量评分系统(FACT-B)对患者生存质量进行评分，治疗组治疗后各项功能较治疗前有明显改善，差异有统计学意义(P＜0.01)；对照组部分功能较治疗前有明显改善，差异有统计学意义(P＜0.01)；治疗后2组各项功能评分比较，差异有统计学意义(P＜0.01)。结论：乳积方配合西药治疗乳腺癌术后患者，可进一步延长患者总生存及无疾病生存时间，改善患者生存质量。
목적：관찰자의유적방방치유선암환자술후복발전이적림상료효。방법：회고성분석109례수술후적유선암환자，근거복약정황분위치료조(유적방배합서약조)57례화대조조(서약조)52례，관찰환자적총생존솔(OS)、무질병생존솔(DFS)、생존질량정황。결과：2조환자재년령、월경상황、병리류형、림상분기、림파결전이정황、격소수체표체정황、Her-2표체정황등기선자료방면，구비방차제성，차이무통계학의의(P＜0.05)。수방시간13～126월，중위수방시간61월；2조3년DFS솔분별위91.4%화68.4%，차이유통계학의의(P＜0.01)；3년OS솔분별위100.0%화97.1%，차이무통계학의의(P＞0.05)；5년DFS솔분별위63.6%화36.8%，차이유통계학의의(P＜0.01)。5년OS솔분별위93.5%화62.5%，차이유통계학의의(P＜0.01)；채용유선암환자생존질량평분계통(FACT-B)대환자생존질량진행평분，치료조치료후각항공능교치료전유명현개선，차이유통계학의의(P＜0.01)；대조조부분공능교치료전유명현개선，차이유통계학의의(P＜0.01)；치료후2조각항공능평분비교，차이유통계학의의(P＜0.01)。결론：유적방배합서약치료유선암술후환자，가진일보연장환자총생존급무질병생존시간，개선환자생존질량。
Objective:To verify therapeutic effects of self-design RuJiFang in preventing postoperative recur-rence and metastasis of patients with breast cancer. Method:The conditions of 109 patients were retrospectively ana-lyzed, and the patients were divided to 57 cases of the treatment group(RuJiFang and western medicine) and 52 cases of the control group(western medicine) according to the medication. Overall survival(OS) rates, disease-free survival (DFS) rates and life qualities of the patients were observed. Result:There was homogeneity of variance existed in the age, menstrual state, pathological types, the phases, lymph nodes, hormone receptor, Her-2 expression and others for the patients of both groups, the difference had no statistical meaning(P<0.05). The follow-up visiting were 13 to 126 months, median follow-ups were 61 months. DFS rates of both groups in three years were respectively 91.4%and 68.4%, the difference had statistical meaning(P<0.01). OS rates in three years were respectively 100.0%and 97.1%, the difference had no statistical meaning (P>0.05);DFS rates of both groups in five years were 63.6%and 36.8%, the difference had statistical meaning(P<0.01). OS rates in five years were 93.5%and 62.5%, the difference had sta-tistical meaning (P<0.01). Life quality of the patients was evaluated with functional assessment of cancer therapy for breast cancer(FACT-B), the scores were improved after treating than before in the treatment group, the difference had statistical meaning (P<0.01);part of the functions in the control group were improved remarkably than before, the difference had statistical meaning(P<0.01);the differences had statistical meaning between both groups in func-tion scores after treating (P<0.01). Conclusion: RuJiFang and western medicine for postoperative patients with breast cancer could improve life quality of the patients and prolong OS time and DFS time.